At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 565 enrolled
Drug / intervention
Travoprost +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multicenter, Randomized, Parallel-Arm, Double Masked, Vehicle Controlled Phase 3A Study Evaluating the Safety and Efficacy of OTX-TP in the Treatment of Subjects With Open-Angle Glaucoma or Ocular Hypertension
In Brief
A Phase 3 clinical trial evaluating Travoprost and Placebo Vehicle for Open Angle Glaucoma and Ocular Hypertension. Completed, enrolled 565 participants across 10 sites.
Detailed Summary
The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle glaucoma or ocular hypertension
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen Angle Glaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartNov 2016
Primary CompletionMar 2019
TodayJul 2026
First PostedSep 26, 2016
Enrollment StartNov 7, 2016
Primary CompletionMar 30, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.8 years ago
Interventions
Travoprostdrug
Placebo Vehicleother